Microsaic Regulatory News (MSYS)

21st March 2018

Microsaic Systems plc

("Microsaic" or the "Company")

Microsaic signs commercial contract with CPI Innovation Services Ltd

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry instruments, is pleased to announce a commercial contract with UK based technology and innovation centre, the Centre for Process Innovation (CPI).

The project will focus on examining the potential of the Microsaic Mass Spectrometry (MS) offering as an online, deployable tool for the elucidation of biopharmaceutical or biologic structure during the manufacturing or bioprocessing workflow. Microsaic's technology is a powerful point of use analysis tool which can be integrated into complex manufacturing workflows, which has the potential to be utilised in upstream cell media, or downstream biologic purification. A typical workflow could benefit from real-time data to drive production optimisation, ensure process control compliance, and reduce risk for the final product.

CPI brings together state of the art facilities and technical expertise to help companies overcome innovation challenges in the manufacture of biologics. CPI is the UK's national technology and innovation centre for the process manufacturing industries. At the National Biologics Manufacturing Centre in Darlington, UK, CPI combines state of the art facilities and technical expertise to support the growth and development of the UK biologics industry and supply chain.

Glenn Tracey, CEO, commented "The UK is well positioned as one of the leading countries for process innovation, especially for high value biologics. It is fitting, therefore, that two high-technology businesses such as Microsaic and CPI, both based in the UK, should embark on such exciting knowledge-based work, paving the way for enabling technologies to meet the future quality and compliance needs in biopharma."

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry (MS) instruments that are designed to improve the efficiency of pharmaceutical R&D. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

Microsaic's core product, the 4500 MiD®, is a robust and compact MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.